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Hydrolysis of plasma arginine to citrulline by arginine deiminase (ADI) was recently shown to suppress lipopolysaccharide-induced
nitric oxide (NO) synthesis. Since arginine is the precursor of NO, and the latter modulates angiogenesis, we explored whether ADI
treatment significantly affected tube-like (capillary) formation of human umbilical vein endothelial cells. Inhibition occurred in a dose-
dependent manner, both in the chorioallantoic membrane and the murine Matrigel plug assay. Inhibition of angiogenesis by ADI was
reversed when a surplus of exogenous arginine was provided, indicating that its antiangiogenic effect is primarily due to arginine
depletion, although other pathways of interference are not entirely excluded. Arginine deiminase is also shown to be as a potent
inhibitor of tumour growth in vitro as in vivo, being effective at nanogram quantities per millilitre in CHO and HeLa cells. Thus, it could
be highly beneficial in cancer therapy because of its two-pronged attack as both an antiproliferative and an antiangiogenic agent.
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Arginine deiminase (ADI; EC 3.5.3.6) catalyses the hydrolysis of L-
arginine to L-citrulline and ammonia (Miyazaki et al, 1990).
Enzyme purified from Mycoplasma arginini inhibits proliferation
of a several types of human cancer cells (Gong et al, 2000; Kang
et al, 2000). Primarily, it would appear through depletion of
arginine, because supplementation of the medium with a plentiful
supply of arginine generally restores cell proliferation (Komada
et al, 1997; Kang et al, 2000). In addition, ADI displays an
antitumour activity in vivo, with seemingly minimal side effects
(Takaku et al, 1992), and is said to inhibit proliferation of human
leukaemia cells more potently than asparaginase (Gong et al,
2000), which is the only amino-acid-degrading enzyme regularly
used in cancer chemotherapy. Nitric oxide (NO) modulates the
activity of vascular endothelial growth factor, basic fibroblast
growth factor, and matrix metalloproteinases during angiogenesis
(Papapetropoulos et al, 1997; Sasaki et al, 1998), although there are
conflicting views (Pipili-Synetos et al, 1994; Raychaudhury et al,
1996; Phillips et al, 2001).
Arginase can also regulate NO level because it is synthesized from
L-arginine in a concentration-dependent manner (Gotoh and Mori,
1999). In fact, at least three enzymes destroy arginine. The second
enzyme is arginine decarboxylase (Philip et al, 2003), and the third
is ADI, which we recently showed to have the ability to deplete
plasma arginine and suppress LPS-induced NO production,
suggesting a potential inhibitory role of ADI in NO-mediated
angiogenesis (Noh et al, 2002; Thomas et al,2 0 0 2 ) .W i l met al
(1996) purified a protein that strongly inhibited proliferation of
vascular endothelial cells, later identified as ADI from Mycoplasma.
Furthermore, in vitro antiangiogenic activity of ADI was recently
reported to inhibit migration and microvessel tube formation in
human umbilical vein endothelial cell cultures (Beloussow et al,
2002). Thus, ADI seems to inhibit tumour growth not only by
exhausting the supplies of a vital nutrient (arginine), but also by its
antiangiogenic activity via suppression of NO generation. We have
therefore examined whether recombinant ADI expressed in
Escherichia coli inhibits in vivo angiogenesis, using several
experimental models. We also report on its effects on tumour cell
growth in the presence or absence of nitric oxide.
MATERIALS AND METHODS
Materials
Cell culture plates were purchased from Corning Costar (Cam-
bridge, MA, USA). Basic fibroblast growth factor (bFGF),
endothelial cell growth supplement, heparin, and Drabkin reagent
kit 525 were from Sigma (St Louis, MO, USA). M199, isopropyl b-
D-thiogalactopyranoside (IPTG) and fetal bovine serum (FBS) were
from Life Technologies (Grand Island, NY, USA). Matrigel was
from BD Biosciences (Bedford, MA, USA), and Sephacryl S-100,
DEAE- and arginine-Sepharose resins were from Amersham
Pharmacia Biotechnology (Piscataway, NJ, USA).
Purification of recombinant ADI
The ADI gene was cloned by polymerase chain reaction (PCR)
using M. arginini genomic DNA. The tryptophan codon TGA in
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sthe coding region that corresponds to a stop codon in E. coli was
changed to TGG by site-directed mutagenesis, using the overlap
extension PCR method (Ho et al, 1989). The mutated ADI gene was
cloned into a pET32a (þ) expression vector (designated pET32a-
ADI) and transformed into E. coli strain BL21. Recombinant ADI
overexpressed as inclusion bodies was denatured with 6 M
guanidine HCl, refolded in 10mM potassium phosphate buffer
(pH 7.4), and purified by DEAE- and arginine–Sepharose column
chromatography (Kang et al, 2000).
Cell culture
CHO, HeLa, and neonatal foreskin fibroblasts (9th passage of a
primary cell culture) cells were grown as stocks in RPMI 1640 with
10% fetal calf serum and antiobiotics. They were transferred to 24-
well plates for growth studies, with the enzyme being incubated in
arginine-deficient RPMI 1640 to which 5% dialysed serum and the
appropriate test substance was added. Amino-acid additions were
made at 400mM. Negative controls were given no arginine
supplementation, but cultures to receive ADI were replete with
arginine. The ADI was normalised in its activities such that its IC50
was set at a level of 0.1Uml
 1, due to changes in specific activity of
the enzyme during shipments to Scotland. The specific activities of
batches 1 and 2 ADI used were originally 58.3 and 46.4Umg
 1
protein, respectively. Effects of cells were seen at 0.1–1Uml
 1.
Better data were obtained with 2Uml
 1, corresponding to higher
ID50 in the range 0.1–1.0ngml
 1 following normalisation, and
agrees well with the data of other groups (e.g. Miyazaki et al, 1990;
Gong et al, 2000). Pegylation of ADI was not carried out for this in
vitro work. Sodium nitroprusside (Sigma, Poole, UK) was added to
the culture medium at a final concentration of between 10 and
250mM, as appropriate.
Avoidance of mycoplasmal contamination. Essential to this
study has been the regular checking of cultures for mycoplasma
contamination. The most devastating effect on cell cultures can be
seen with arginine deiminase released from M. arginini as a
contaminant. Using the Roche Mycoplasma Detection Kit for four
prevalent species of Mycoplasma that includes M. arginini, cultures
were tested before experimentation, according to the manufac-
turer’s instructions. The only cell line that occasionally showed
positive M. arginini results was HeLa, and fresh uncontaminated
cultures were selected for the present work (see Figure 7).
However, we also used a supernatant preparation from a pure
culture of M. arginini provided by Dr Robin Nicholas (Veterinary
Laboratories Agency, Weybridge, UK) for comparison with
recombinant ADI from E. coli.
Growth was measured daily by electronic (Coulter) counting of
the cells in three wells per data point. Averages were plotted with one
standard deviation of the mean shown in each case. Where bar lines
do not appear, they will be within the symbols used on the graphs.
Tube formation assay
Human umbilical vein endothelial cells (HUVECs) were prepared
from freshly delivered cords (Jaffe et al, 1973) and confirmed by
immunocytochemical staining for Factor VIII. The cells were
cultured in 25cm
2 flasks in M199 media supplemented with 10%
FBS, 100Uml
 1 penicillin, 100mgml
 1 streptomycin, 50mgml
 1
endothelial cell growth supplement, and 50mgml
 1 heparin in a
371C incubator with humidified atmosphere containing 5% CO2.
The cells between passages 3 and 5 were used for in vitro
experiments. Capillary-like tube formation assay was performed as
described previously (Grant et al, 1992), but with the following
modifications. The 48-well plates were coated with 200ml Matrigel
(10mgml
 1) by incubating at 371C for 1h. Human umbilical vein
endothelial cells were suspended in M199 media supplemented
with 10% FBS, and plated onto a layer of Matrigel at a density of
4 10
4cellswell
 1 with or without ADI. The plates were incubated
for a further 18h at 371C, and capillary-like tube formation was
observed microscopically, their area of being measured using
Image-Pro Plus software (Media Cybernetics, Silver Spring, MD,
USA).
CAM assay
Fertilised chicken eggs were incubated at 37
oC in a humidified
incubator. On the third day of incubation, 2ml of albumin was
aspirated from the eggs with an 18-gauge hypodermic needle to
detach the developing CAM from the shell. On the fourth day, the
shell was punched out to make a window and sealed with a
cellophane tape. Thermanox coverslips (Nunc, Naperville, IL,
USA) coated with or without 0.046U ADI were applied to the CAM
surface through the windows for 2 days. After injection of an
appropriate volume of 10% fat emulsion (intralipose) into the
chorioallantois, angiogenesis in CAM was observed under a
microscope, with 420 eggs being used for each assay.
In vivo Matrigel plug assay
Male C57BL/6 mice (7 weeks old) were supplied from Daehan
Biolink Co. (Seoul, South Korea). Matrigel plug assay in mice was
performed as described previously (Passaniti et al,1 9 9 2 ) .B r i e f l y ,
0.4ml of Matrigel containing 0.46Uml
 1 ADI, 50ngml
 1 bFGF, and
60Uml
 1 heparin were injected subcutaneously near the abdominal
midline of the mice using a 25-gauge needle. Control animals were
subjected to subcutaneous injection of Matrigel mixture without
ADI. Where heparin and bFGF were used, these were added along
with the Matrigen inoculation. After injection, the Matrigel rapidly
formed a solid gel at the site of injection. Plugs were separated from
the abdominal wall after 5 days and fixed with 3.7% formaldehyde in
phosphate-buffered saline. The formalin-fixed Matrigel samples
were embedded in paraffin and examined with Masson-trichrome
stain. To evaluate new blood vessel formation, haemoglobin content
was measured with a Drabkin reagent kit 525. The concentration of
haemoglobin was calculated from a known amount of haemoglobin
assayed in parallel. The experiment was repeated twice with five
mice in each group.
RESULTS
Expression and purification of recombinant ADI
Recombinant ADI gene was expressed in E. coli as a thioredoxin
fusion protein with His-tag and S-tag, using a pET32a (þ)
expression vector. Thioredoxin–ADI fusion protein was accumu-
lated in the cytoplasm as inclusion bodies and its molecular weight
was estimated at 64kDa (Figure 1A; this is included here to show
the authenticity of the batches of enzyme prepared for the present
work). However, the fusion protein tended to be self-degrading
during the process of denaturation and refolding for purification.
Although the precise cleavage site of self-digestion in the linker
region was not determined, enough enzyme activity was retained
to hydrolyse arginine. However, this gave a much lower specific
activity than for recombinant arginase (Philip et al, 2003). Our
recombinant ADI was estimated at 49kDa on SDS–PAGE and
98kDa by Sephacryl S-100 gel filtration (Figure 1A and B),
indicating the same dimeric structure as native ADI purified from
M. arginini (Takaku et al, 1992). After DEAE–Sepharose and
arginine-affinity column chromatography, B5mg active ADI was
purified from 1l of culture.
Inhibition of capillary-like tube formation of HUVECs by
ADI
To examine the effect of ADI on tube formation by vascular
endothelial cells, HUVECs were plated on the Matrigel-coated
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sculture dishes and treated with ADI from 0.012 to 0.46Uml
 1.
Capillary-like tube formation, an indication of in vitro angiogen-
esis, was well developed in control HUVECs after 18h of
incubation (Figure 2A). Arginine deiminase treatment significantly
inhibited the capillary-like tube formation of HUVECs in a dose-
dependent manner compared with controls (Figure 2A). The
percentage of tubule area after 18h treatment from 0.012 to
0.46Uml
 1 ADI ranged from 76 to 16% of the control values
(Figure 2B). To characterise the antiangiogenic effect of ADI, 2mM
arginine was added to the culture media containing 0.46Uml
 1
ADI. Tube formation resumed following the exogenous arginine,
whereas no new tube formation appeared in controls not
supplemented with arginine (Figure 3).
Inhibition of angiogenesis by ADI in vivo
To determine the in vivo antiangiogenic effect of ADI, CAM and
Matrigel plug assays were carried out. At 0.046Uml
 1, ADI
significantly inhibited chick embryonic angiogenesis, producing
an avascular zone beneath the disk in 88% of the ADI-treated
group, whereas control CAMs treated with saline showed no
disturbance of angiogenesis (Figure 4). In addition, ADI inhibition
was quantitatively estimated using the in vivo mouse Matrigel plug
assay. After 5 days of implantation, the control – Matrigel plugs
containing bFGF and heparin without ADI appeared dark red in
colour due to massive formation of blood vessels. Matrigel plugs
treated with 0.46Uml
 1 ADI in combination with bFGF and
heparin remained pale, indicating no blood vessel formation
(Figure 5A). Haemoglobin content in the Matrigel plugs was taken
as a measure of vasculature formation; the content in control
Matrigel without ADI was 75.2713.8gdl
 1 (n¼5), whereas
Matrigel with 0.46Uml
 1 ADI was 2.570.1gdl
 1 (n¼7,
Figure 5B), indicating that ADI inhibited growth factor-induced
angiogenesis in this model by B97%.
In experiments testing the effect of the spontaneous nitric oxide
generator, sodium nitroprusside, both HUVEC and fibroblasts in
angiogenesis co-culture (Bishop et al, 2000) tolerated the upper
range of our treatment very well (10–500mM), and there was no
obvious effect of tubule formation throughout their period of
development (14 days) in the co-culture system, whether or not
sodium nitroprusside was added to the medium being replaced
every other day (data not shown).
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Figure 1 SDS–PAGE and gel filtration analysis of recombinant ADI. (A)
Thioredoxin–ADI fusion protein expressed in E. coli was resolved by 10%
SDS–PAGE. Lane 1; molecular weight marker proteins, lane 2; crude
extract without IPTG induction, lane 3; inclusion body after IPTG induction,
lane 4; elute from arginine-affinity column chromatography. (B) Molecular
weight of the self-digested ADI was determined by calibrated Sephacryl S-
100 gel filtration; standard markers A: bovine gamma globulin (Mr 158kDa),
B: chick ovalbumin (Mr 44kDa), and C: equine myoglobin (Mr 17kDa), D:
vitamin B12 (Mr 1.35kDa).
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Figure 2 Inhibitory effect on tube formation of human endothelial cells
by ADI. HUVECs were plated on Matrigel-coated wells at a density of 4 x
10
4 cellswell
 1 with various amounts of ADI (0.012–0.46Uml
 1; i.e. 0.4–
10mgml
 1). The plates were further incubated for 18h at 371C, and
capillary-like tube formation was photographed using microscope (A). The
area showing capillary-like tube formation was measured by Image-Pro Plus
software (Media Cybernetics, Silver Spring, MD, USA) and represented as
percentage of the control value (B). The values are means7s.e. (n¼3
independent experiments performed in duplicate).
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sInhibition of tumour cell growth by ADI
We reasoned that if inhibition of tumour cell growth by ADI in
vitro was primarily and largely due to depletion of arginine, the
responses of two of the three carefully chosen cell lines would be
decidedly different (Wheatley and Campbell, 2003). We have tested
ADI on many cells lines and found that it inhibits growth and/or
kills cells as effectively as arginase treatment (Scott et al, 2000), but
we have confined our experiments here to these two because they
represent the ends of a spectrum of the ability of cells to utilise
citrulline. Thus, ADI should be highly effective against cells that
are incapable of metabolising citrulline in lieu of arginine, the
selection therefore being the CHO cell line. However, whether
citrulline is produced by ADI or exogenous citrulline is added to
the culture medium of cells that can metabolise it to arginine, ADI
should be less effective. HeLa cells can metabolise exogenous
citrulline, although a concentration B2 times greater than arginine
is needed to sustain a comparable growth rate (Philip et al, 2003).
Data from a comparative experiment with ADI clearly show its
greater damaging action on CHO than HeLa cells (Figure 6). The
sensitivity of CHO to the ADI in Figure 7 includes curves for
cultures set up at time zero in arginine-free medium, to which
arginine was either added at the same time as the enzyme at two
comparable ADI levels (dashed lines) or omitted (solid lines). In
cultures that initially had arginine-replete medium, ADI was more
toxic than those without (see Discussion).
The data accord well with observations on cell lines made where
contamination with M. arginini has occurred, as described below.
We checked the effect of supernatants from cultures of M. arginini
on HeLa cells and fetal fibroblasts to show that medium with
known high levels of ADI were inhibitory not just to HeLa cells,
but to normal cells (Figure 8). This experiment confirms that the
enzyme expressed was ADI, and that when this organism invades
HeLa cultures, the cells fail to thrive after normal subculturing
procedures and quickly die. We therefore took an authentic
preparation of ADI as the supernatant of a pure-type cultures
collection of M. arginini from Dr Robin Nicholas (National
Microbiological Standards Centre, Weybridge, UK), and show here
that normal cells that convert citrulline to arginine (see Philip et al,
2003) and grow more slowly than many tumour cells lines are
nevertheless inhibited by ADI at approximately comparable doses,
although cell death is much less extensive in the normal cells than
in HeLa cells. This contrasts with fibroblasts deprived of arginine
by medium formulation, in which virtually no cell death occurred
over 3 days of incubation (Figure 8; see Discussion).
We also used HeLa cells to show that, where arginine is depleted
and a restricting level of citrulline slows or arrests growth due to
ADI, this effect occurs independently of NO reduction. This was
done by carrying out studies on HeLa cells in the presence of ADI
at lower levels of arginine (100–250mM) with or without the
presence of a NO donor, sodium nitroprusside, present at
equivalent concentrations, which made no difference to the
resulting depression of growth (therefore data not shown; see
Discussion). N.B. At 100–250mM, a few cells were damaged in the
early treatment of controls, but there was no increased (synergistic
or additive) effect of ADI treatment.
DISCUSSION
Antiangiogenic effects
Recombinant ADI from E. coli inhibits angiogenesis in two
different experimental systems. Arginine deiminase suppressed
in vitro capillary-like tube formation of vascular endothelial cells
and in vivo neovascularisation in the CAM and the Matrigel plug
assays in the mouse. This microbial enzyme, ADI, specifically
hydrolyses arginine to citrulline, leading to depletion of an
essential amino acid that is utilised not only for protein synthesis,
but also is a substrate for NO, polyamine, proline, and glutamate
production in mammals (Wu and Morris, 1998). Deprivation of
extracellular arginine by ADI treatment inevitably disrupts a
number of biochemical pathways, including some intracellular
regulatory signals for endothelial cell growth. Although an
Control Control + 2 mM Arg
ADI 10 g ml−1 ADI 10 g ml−1 + 2mM Arg
Figure 3 Recovery of angiogenesis by supplement of arginine. Arginine (2mM) was added to the culture of HUVECs treated with 0.46Uml
 1
(10mgml
 1) ADI to examine the antiangiogenic effect by arginine depletion. Tube formation suppressed by ADI treatment was restored after supplement of
arginine. Each sample was assayed in triplicate and the assays were repeated twice.
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santiangiogenic activity of NO has been reported (Raychaudhury
et al, 1996; Philip et al, 2001), several investigators showed a
positive association of NO level with angiogenic activity (Papape-
tropoulos et al, 1997; Murohara et al, 1998). Interestingly,
overexpression of arginase, another arginine-degrading enzyme,
markedly inhibits NO synthesis and enhances polyamine produc-
tion in endothelial cells by modulating intracellular arginine
availability (Li et al, 2001). Thus, it can be assumed that the
antiangiogenic effects of ADI are associated with NO suppression
resulting from depletion of arginine. Inhibition of capillary-like
tube formation of vascular endothelial cells by ADI treatment is
more likely to be due to the depletion of arginine, since exogenous
arginine supplementation reversed its inhibitory effects. We found
no evidence that the lack of NO production as a consequence of
arginine deprivation has any significant effect of the angiogenic
process in the presence or absence of ADI.
In addition to NO suppression per se being not relevant in this
context, arginine depletion by ADI treatment would alter levels of
polyamines, proline, and glutamate. As polyamines are essential
for proliferation of endothelial cells (Morrison et al, 1995), their
decreased synthesis may also affect angiogenesis. In fact, a-
difluoromethylornithine (DFMO), an irreversible inhibitor of
ornithine decarboxylase, a rate-limiting enzyme in the polyamine
biosynthesis, inhibited proliferation of HUVECs (Takahashi et al,
2000). Thus, decreased polyamine synthesis due to ADI treatment
will no doubt exacerbate the antiangiogenic action.
Antitumour action
With regard to the suppression of tumour cell growth by ADI, our
findings clearly indicate that cells behave the same way whether or
not NO is present, unlike endothelial cells. The inhibitory action of
the enzyme will be principally due to a drastic limitation of
arginine that accounts for CHO and HeLa cells being arrested in
growth, and both of these lines undergo considerable death
because malignant cells fail to reach quiescence (Scott et al, 2000).
However, this does not necessarily explain the damaging as
Control
ADI
Figure 4 Antiangiogenic effect of ADI on the chick CAM. Arginine
deiminase (0.046U) was loaded in Thermanox coverslips, air-dried and
applied to the CAM surface of fertilised eggs (Materials and methods). An
avascular zone of the CAM beneath the disk (surrounded by arrows) was
produced 2 days after treatment of ADI, but not in control disk. At least 20
eggs were used for each assay.
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Figure 5 Inhibition of angiogenesis by ADI in vivo mouse Matrigel assay.
Matrigel (0.4ml) containing 50ngml
 1 of bFGF and 60Uml
 1 of heparin in
combination with or without 0.46Uml
 1 ADI was subcutaneously injected
near the abdominal midline of the mice. (A) Histological analysis of Matrigel
implants (for experimental procedures, see Materials and methods).
Matrigel without ADI (A and B) showed formation of blood vessels with
various sizes (arrows) forming in the Matrigel. Inside the vessel, red blood
cells were observed (red colour in the vessel). However, ADI treatment
clearly inhibited blood vessel formation (C and D). *Indicates connective
tissues surrounding Matrigel implants. (A and C: haematoxylin–eosin
staining, B and D: Masson-Trichrome staining). Original magnification x100.
(B) Haemoglobin content in the Matrigel was measured with Drabkin
reagent kit 525 to evaluate blood within the vessels formed 5 days after
injection, calibrated against a known amount of haemoglobin in parallel.
ADI potently inhibited growth factor-induced angiogenesis by 97%. Each
value represents the mean7s.e.of five ADI-treated animals and seven per
control group.
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sopposed to arresting action of ADI on normal fibroblasts
(Figure 8). Furthermore, we see the damaging action of ADI being
manifest here not so much in the absence of arginine (in the
negative controls), as when it has acted upon arginine from the
start of the incubation. Although we have not proved that the
release of nascent NH3 (not ammonium ions) as the by-product of
arginine degradation by ADI is responsible, this interpretation
seems reasonable. When we consider the effect on CHO and HeLa
cells (Figures 6–8), it is noteworthy that tumour cells are
particularly affected at critical ADI concentrations, once again
presumably through the release of nascent NH3. When arginine is
present rather than absent and ADI is added critically at B0–2to
0.4Uml
 1, both elements are clearly involved, and thus it is not an
‘either/or’ situation, but one where both apply, resulting in the
more devastating effect of ADI in the presence of arginine. This is
in good agreement with the data of Gong et al (2000) and others
reporting massive cell death with ADI (Komada et al, 1997),
although not entirely with their interpretation.
Native ADI
We also checked that the purified enzyme prepared from E. coli
possessed all the characteristics of authentic ADI originating from
a pure strain of M. arginini (Figure 8). The evidence is a salutary
reminder that cultures of cells need to be regularly checked for M.
arginini because the ADI released from these organisms in
considerable quantities devastates cultures of both normal and
malignant phenotypes.
It is most unlikely that NO being produced through the action of
other enzymes on arginine (NO synthase) plays a role in tumour
cell death. Sodium nitroprusside at concentrations that should
release very considerably greater amounts of NO into a closed
culture system would not be expected to show toxicity until
B100mM, and it is already known that some cell types such as rat
lung epithelial cells (Bundschuh et al, 1995) tolerate 2.6mM
sodium nitroprusside. We found some occasional cell damage
soon after treatment at 100mM and a little more at 250mM, but this
was neither additive nor synergistic in nature. The absence of NO
would not in any way have been responsible for helping cells to
survive the effect of arginine deprivation induced by ADI.
Previously, ADI was reported to have in vivo antitumour activity
(Takaku et al, 1992), especially in leukaemia. Gong et al (2000)
claimed it was more effective than L-asparaginase, but did not to
take into account the widely disparate specific activities of the two
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Figure 7 Dose–response curves for ADI on CHO cells with (solid lines)
and without arginine (broken lines). Effect of increasing concentrations of
ADI from 0.01 to 1Uml
 1 (see inset box) on CHO cells from an inoculum
of 50000 cells per well (100%), and expressed daily as a percentage
relative to the control (&). The dashed curve (- - m - -) gives data for a
culture in which 0.1Uml
 1 ADI were added but without 400mM arginine
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those given arginine and enzyme were dead within 3 days.)
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Figure 8 Action of ADI on fetal foreskin fibroblasts and HeLa cells. HeLa
and FF9 cells were cultured in 24-well plates from a 25000 cells per well
inoculum. After 1 day, they were treated with supernatant from a M.
arginini culture prepared for us by Dr Robin Nicholas. Argenine deiminase
activity was 0.2–0.25Uml
 1 in the media added to the cultures. The
cultures were left 3 days before the number of cells were estimated and
expressed as a percentage of the controls taken as 100% of the initial value.
The square symbols refer to HeLa cells, with the solid line being cultures
with arginine present, while the negative controls (no arginine, but the same
amount of ADI) has the dashed line. The symbol for FF9 fibroblasts is a
closed circle, and the dashed and the solid lines are as for the HeLa
cultures. In both cases, cells did worse where arginine was degraded by ADI
than when it was absent. Means are plotted of triplicate values and the bar
lines give 1 s.d.
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senzymes (Wheatley and Campbell, 2002), comparing them only on
a mass per volume basis. Arginine is one of the essential nutrients
for mammalian cells and the first amino acid depleted by cell
metabolism in culture (Wheatley et al, 2000). The rapid depletion
of arginine may be partly due to the fact that arginine is less
efficiently recycled (especially residues recovered from catabolised
proteins) by cultured cells than other amino acids, but the kinetics
of this recycling have yet to be determined in animals where
tumours have been inhibited by ADI. The reutilisation of citrulline
following ADI action remains a worrying aspect of its efficacy, but
will always depend on an intact urea cycle (lacking in many
tumour cell types, Wheatley and Campbell, 2003).
General conclusions
Upon deprivation of arginine, normal diploid fibroblasts having
stringent check points of cell cycle can survive for several days in a
quiescent state (G0) after exiting from cell cycle, whereas tumour
cells lacking stringent regulatory cell cycle checkpoint fail to enter
quiescence and continue to divide until cell death intervenes
through some form of imbalance and/or apoptosis (Scott et al,
2000; Wheatley et al, 2000). Thus, deprivation of arginine by ADI
could induce detrimental pleiotypic responses and lead to prompt
tumour cell death by disrupting the biochemical pathways of the
cell cycle. In addition to its antiproliferative effect on tumour
growth, we demonstrated that ADI suppressed angiogenesis by
inhibiting both tube formation of endothelial cells and neovascu-
larisation in CAM and Matrigel plug assay. Since the latter does not
require cell proliferation, the action of arginine degrading enzyme
may play other roles than simply reducing the availability of
arginine as a precursor in these and other pathways that have not
already been mentioned. Solid tumours could not proliferate
continuously without recruiting a blood supply by angiogenesis
(Folkman et al, 1995). These results suggest that ADI could
synergistically inhibit in vivo solid tumour growth by the
combined action of antiproliferative activity through the depletion
of arginine as a nutrient and its own antiangiogenic activity.
However, it is also clear that the different strands of this complex
process need to be teased out and subjected to a more thorough
analysis, especially the rate of citrulline recycling.
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